Duodenal levodopa infusion for the treatment of Parkinson’s disease
- 22 March 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 8 (5), 657-664
- https://doi.org/10.1517/14656566.8.5.657
Abstract
Motor fluctuations are a common problem in the long-term management of Parkinson's disease (PD), resulting in disability and impaired quality of life. The relatively short serum half-life (approximately 90 min) of oral levodopa/carbidopa and its erratic absorption due to delayed and inconsistent gastric emptying (a non-motor feature of PD) are thought to be important factors in the development of motor fluctuations. Continuous infusion of levodopa/carbidopa directly into the small intestine of PD patients results in marked reduction of motor fluctuations by reducing plasma levodopa variability by an order of magnitude over oral therapy. Previously, the use of long-term intraduodenal infusion of levodopa/carbidopa was limited by the relatively large volumes of infusate necessitated by the low solvency of levodopa. The development of a micronized levodopa (20 mg/ml) and carbidopa (5 mg/ml) suspension utilizing a methylcellulose gel provides the high levodopa concentration and physical and chemical stability necessary for long-term enteral therapy. Clinical evidence indicates that a marked reduction of motor fluctuations and dyskinesias can be achieved and maintained by intraduodenal administration of this suspension. This article reviews the published data describing the efficacy and safety of duodenal levodopa, and discusses its current and potential role in meeting the needs of PD patients.Keywords
This publication has 46 references indexed in Scilit:
- Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopaMovement Disorders, 2006
- Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primatesMovement Disorders, 2005
- Impact of the motor complications of Parkinson's disease on the quality of lifeMovement Disorders, 2004
- Treatment interventions for Parkinson's disease: an evidence based assessmentThe Lancet, 2002
- Pramipexole vs Levodopa as Initial Treatment for Parkinson DiseaseJAMA, 2000
- A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or LevodopaNew England Journal of Medicine, 2000
- Immediate-release and controlled-release carbidopa/levodopa in PDNeurology, 1999
- The response to levodopa in parkinson's disease: Imposing pharmacological law and orderAnnals of Neurology, 1996
- Duodenal and gastric delivery of levodopa in parkinsonismAnnals of Neurology, 1988
- Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobilityNeurology, 1988